Digital diabetes management devices, like smart insulin pens, smart insulin pumps, smart glucose meter, and continuous blood glucose monitoring devices, help people with diabetes (type I and II) to monitor and manage their glucose levels. Thus, with the increasing prevalence of diabetes across the globe, the demand for technologically advanced diabetes management devices (digital diabetes management devices) is also increasing with a rapid pace.

Market Dynamics:

Rise in burden of diabetes, growing geriatric population, introduction of artificial intelligence (AI) in diabetes management devices, increasing demand for digital diabetes management devices, and increasing awareness among people about diabetes care and benefits of technologically advanced diabetes management devices are major factors expected to propel the growth of the global digital diabetes management market over the forecast period.

For instance, in November 2022, Eli Lilly and Company (LLY) planned to rollout first connected platform, the Tempo Personalized Diabetes Management Platform, in the U.S. The platform aims to help individuals living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins.

Moreover, in March 2022, India Medtronic Private Limited announced the launch of the MiniMed 780G system in India. The MiniMed 780G system is a next generation closed loop insulin pump system for the treatment of type 1 diabetes in people age 7 to 80 years.

Key features of the study:

• This report provides in-depth analysis of the global digital diabetes management market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global digital diabetes management market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Abbott Laboratories, Acon Laboratories, Inc., Bayer AG, F. Hoffmann-la Roche Ltd., Johnson and Johnson, Medtronic Plc, Novo Nordisk A/S, Terumo Corporation, Dexcom, Inc., and Becton, Dickinson and Company, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global digital diabetes management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital diabetes management market.

Detailed Segmentation:

• Global Digital Diabetes Management Market, By Type:
  • Handheld Devices
  • Wearable Devices
• Global Digital Diabetes Management Market, By Product:
  • Continuous Blood Glucose Monitoring Systems
  • Smart Glucose Meter
  • Smart Insulin Pumps
  • Smart Insulin Pens
  • Apps
• Global Digital Diabetes Management Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Bayer AG
  • F. Hoffmann-la Roche Ltd.
  • Johnson and Johnson
  • Medtronic Plc
  • Novo Nordisk A/S
  • Terumo Corporation
  • Dexcom, Inc.
  • Becton, Dickinson and Company